You are here
Encouraging results for PD-1 inhibition in gastric cancer
Smyth EC, Cunningham D.
Lancet Oncol. 2016 June [Epub ahead of print]
The prognosis for advanced gastric cancer is poor: less than 10–15% of patients with metastases live for more than 2 years. Trastuzumab and ramucirumab have resulted in modest improvements in overall survival for patients with HER2-positive gastric cancer and in the second-line setting, respectively.1–2 However, these drugs are notable for their success in a field in which there have been many failures.1–4 Within this challenging therapeutic context, the results of the KEYNOTE-012 study by Kei Muro and colleagues5 are promising.